Welcome to our dedicated page for Firsthand Technology Value Fund news (Ticker: SVVC), a resource for investors and traders seeking the latest updates and insights on Firsthand Technology Value Fund stock.
Firsthand Technology Value Fund Inc (SVVC) delivers technology-focused investment solutions through rigorous analysis of emerging innovations. This news hub provides stakeholders with official updates and market insights directly from the company.
Access SVVC's latest press releases, earnings reports, and strategic announcements in one centralized location. Track developments including portfolio company milestones, leadership changes, and sector-specific market analysis. Our curated collection serves as a reliable resource for understanding the fund's positioning within evolving tech markets.
Key updates cover investment decisions, partnership formations, and operational adjustments that reflect SVVC's value-driven philosophy. Bookmark this page for real-time access to critical information influencing technology investment landscapes. Return regularly to stay informed about developments shaping this active management firm's trajectory.
Firsthand Technology Value Fund (NASDAQ: SVVC) reported its Q2 2021 financial results, showing net assets of approximately $107.3 million, or $15.57 per share, down from $112.4 million, or $16.31 per share in Q1. The Fund's portfolio includes public and private securities valued at about $102.5 million. Investment income for the quarter was approximately $1.4 million with net investment income of around $554 thousand. However, the Fund experienced net realized and unrealized losses of approximately $5.6 million. The management continues to strategize for portfolio enhancement.
Firsthand Technology Value Fund (NASDAQ: SVVC) announced its preliminary net asset value (NAV) of $15.57 per share as of June 30, 2021. The fund's top five investments include IntraOp Medical, Pivotal Systems, Wrightspeed, Revasum, and Hera Systems, comprising 90.5% of the fund's preliminary net assets. The total investment is reported at $102.5 million, equating to approximately $14.87 per share. Cash and cash equivalents are approximately $0.50 per share. Detailed financial statements will be released with the upcoming quarterly report.
Firsthand Technology Value Fund (NASDAQ: SVVC) announced its top five holdings as of May 31, 2021, which represent 87.4% of the Fund's estimated total investments of approximately $112 million. The leading investment is in IntraOp Medical, accounting for about 26.7% of total investments, followed by Wrightspeed at 25.7%, Pivotal Systems at 21.5%, Revasum at 9.9%, and Hera Systems at 3.6%. The estimated value per share stands at $16.21, with cash and equivalents at approximately $0.77 per share. A detailed financial report will be available in August 2021.
Firsthand Technology Value Fund (SVVC) announced its Q1 2021 results, reporting net assets of approximately $112.4 million, or $16.31 per share, compared to $102.1 million at year-end 2020. The portfolio consisted of investments valued at $111.2 million and cash equivalents of $0.5 million. The Fund generated investment income of approximately $1.3 million and net investment income of around $508 thousand. Notably, the Fund recorded net gains of $9.8 million on investments.
Firsthand Technology Value Fund (NASDAQ: SVVC) announced a preliminary NAV of $16.31 as of March 31, 2021. The Fund's top five holdings include Pivotal Systems (27.3%), IntraOp Medical (25.7%), Wrightspeed (23.6%), Revasum (11.2%), and Hera Systems (3.3%), collectively comprising 91.1% of its net assets. Total investments reached $111.2 million or approximately $16.14 per share. Cash equivalents stand at $0.07 per share. A full report will be available in May 2021.
Firsthand Technology Value Fund (NASDAQ: SVVC) announced its fiscal results for 2020, showing a significant decline in net assets from $127.1 million ($17.70 per share) in 2019 to $102.1 million ($14.82 per share) in 2020. The investment income was approximately $3.7 million, while the fund reported net realized and unrealized losses of about $23.6 million. The portfolio included $99.7 million in equity/debt investments and $2.37 million in cash equivalents. The Valuation Committee adjusted the fair values of private companies considering performance and market changes.
As of February 28, 2021, Firsthand Technology Value Fund (NASDAQ: SVVC) disclosed its top five holdings comprising IntraOp Medical, Pivotal Systems, Wrightspeed, Revasum, and SVXR, which together accounted for 90.7% of the Fund's estimated total investments of approximately $109 million, or $15.77 per share. IntraOp Medical represents the largest stake at about 24.3%, followed closely by Pivotal Systems at 23.6%, and Wrightspeed at 23.0%. A comprehensive financial report will be available in May 2021.
Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings as of January 31, 2021, which encompass approximately 89.4% of its estimated total investments of $108 million, translating to $15.68 per share. The leading investment is in IntraOp Medical Corp. at 24.4%, followed by Wrightspeed, Pivotal Systems, Revasum, and SVXR. The fund holds various securities including preferred stocks and debt across these companies. More details will be disclosed in the upcoming quarterly report due in May 2021.
Firsthand Technology Value Fund (NASDAQ: SVVC) announced its preliminary net asset value (NAV) of $14.82 per share as of December 31, 2020. The Fund's top five holdings include IntraOp Medical, Wrightspeed, Pivotal Systems, Revasum, and SVXR, which together account for 88.7% of the Fund's total investments. Notably, IntraOp Medical represents 25.8% of the Fund's assets, the largest share. Total investments reached $99.7 million, or approximately $14.46 per share. The annual report will be filed by March 2021.
Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings as of November 30, 2020, which include Pivotal Systems, IntraOp Medical, Wrightspeed, Revasum, and SVXR. Collectively, these holdings represent 89.7% of the fund's estimated total investments of approximately $102 million, translating to about $14.78 per share. Notably, Pivotal Systems accounts for 29.1% of this total, followed by IntraOp Medical at 21.7%. Full financial details will be disclosed in its annual report in March 2021.